All In Biotech

NDA 204760 · Averitas

Movantik

Naloxegol Oxalate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Apr 13, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Sep 16, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

0 Phase 3, 0 recruiting

FAERS reports

3,970

1,878 serious, 288 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2026.

MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. MOVANTIK is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. (1)

Mechanism: Naloxegol is an antagonist of opioid binding at the mu-opioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in tissues, such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone and is a substrate for the P-glycoprotein transporter (P-gp). Also, the presence of the PEG moiety in naloxegol reduces its passive permeability as compared with naloxone. Due to the reduced permeability and increased efflux of naloxegol across the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MOVANTIK · NALOXEGOL OXALATE EQ 25MG BASE · TABLET, ORAL · Prescription
  • MOVANTIK · NALOXEGOL OXALATE EQ 12.5MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Naloxegol Oxalate" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea386
  • constipation384
  • drug ineffective377
  • pain367
  • nausea332
  • off label use275
  • abdominal pain264
  • abdominal pain upper229
  • intentional product misuse224
  • vomiting210
  • death188
  • fatigue187

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
20112
20121
20134
20142
2015371
2016675
2017575
2018352
2019300
2020254
2021263
2022235
2023235
2024254
2025271
2026174

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Movantik (Naloxegol Oxalate)

2024 spending

$153M

Beneficiaries

80,688

336,315 claims

Per beneficiary

$1,900

$13.50 per unit

View as table
YearSpending
2020$12,413,099
2021$93,535,593
2022$121,381,425
2023$140,596,853
2024$153,330,440

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Averitas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.